Prostate-specific membrane antigen radioligand therapy of prostate cancer

Mohsen Beheshti*, Alexander Heinzel, Dirk von Mallek, Christian Filss, Felix M. Mottaghy

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

Abstract

Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still chal-lengina in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with beta- or alpha-emitters such as 177-Lutethium (Lu-177) or 225-Actinium ((225)A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics. clinical performance, safety and toxicity of PSMA targeted beta- or alpha-radiation therapy.

Original languageEnglish
Pages (from-to)29-36
Number of pages8
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume63
Issue number1
DOIs
Publication statusPublished - Mar 2019

Keywords

  • Prostatic neoplasms
  • Lu-177-PSMA-617
  • Radiotherapy
  • TARGETED ALPHA-THERAPY
  • RADIATION-DOSIMETRY
  • PSMA LIGANDS
  • PRECLINICAL EVALUATION
  • RADIONUCLIDE THERAPY
  • PHASE-II
  • BIODISTRIBUTION
  • INHIBITORS
  • PET
  • ANTIBODY

Cite this